

Please enter the following amendments:

IN THE CLAIMS:

1. (Amended) A method for inhibiting the proliferation of mammalian cells that express an A_{2B} adenosine receptor comprising administering a therapeutically effective amount of an A_{2B} adenosine receptor antagonist to the mammalian cells, whereby the proliferation of cells is inhibited.

3. (Amended) The method of claim 2 wherein the vascular endothelial cells that express the A_{2B} adenosine receptor are selected from the group consisting of coronary endothelial cells and endothelial cells from the vascular bed.

5. (Amended) The method of claim 4 wherein the vascular bed endothelial cells are retinal endothelial cells.

11. (Amended) The method of claim 1 wherein the A_{2B} adenosine receptor antagonist is administered in an amount ranging from about 1 microgram/kg to about 50 milligrams/kg.

12. (Amended) The method of claim 1 wherein the A_{2B} adenosine receptor antagonist is administered in an amount ranging from about 1 microgram/kg to about 10 milligrams/kg.

14. (Amended) The method of claim 1 wherein the A_{2B} adenosine receptor antagonist is administered in eye drops.

Remarks

The Amendments

Claim 1 has been amended to include a final step that relates back to the preamble. Claim 3 has been amended to add a conjunction between "coronary endothelial cells" and "endothelial cells from the vascular bed." Claim 5 has been amended to provide proper antecedent basis for